About
Titles
Assistant Professor Adjunct
Appointments
Medical Oncology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Solomon Langermann's published research.
Publications Timeline
A big-picture view of Solomon Langermann's research output by year.
Anne Chiang, MD, PhD
David Rimm, MD, PhD
Roy S. Herbst, MD, PhD
Sarah Goldberg, MD, MPH
7Publications
4Citations
Publications
2024
A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
Christenson E, Mahadevan D, Kazmi S, Manda S, Sohal D, Hutson T, Fu S, Martz A, Kordahi S, Barbu E, Flies D, Langermann S, Chisamore M, Gutierrez M, Matrana M, Spira A, Wadlow R, Guha U, Myint H, Le D. A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. Journal Of Clinical Oncology 2024, 42: 2538-2538. DOI: 10.1200/jco.2024.42.16_suppl.2538.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune cell infiltrationOvarian cancerColorectal cancerICI therapyCell infiltrationAdvanced metastatic colorectal cancerPromote immune cell infiltrationResistance to ICI therapyEffector memory T cellsPeripheral blood immunophenotypingPhase 1b/2 studyDose of pembrolizumabData cut-offMetastatic colorectal cancerMetastatic solid tumorsMemory T cellsColorectal cancer subjectsImmune cell functionHuman IgG1 Fc domainAnti-tumor activityTumor extracellular matrixModified toxicity probability intervalExtracellular matrixCheckpoint inhibitorsThe FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies
Prajapati K, Yan C, Yang Q, Arbitman S, Fitzgerald D, Sharee S, Shaik J, Bosiacki J, Myers K, Paucarmayta A, Johnson D, O’Neill T, Kundu S, Cusumano Z, Langermann S, Langenau D, Patel S, Flies D. The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies. Science Advances 2024, 10: eadj4698. PMID: 38427724, PMCID: PMC10906930, DOI: 10.1126/sciadv.adj4698.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsFibronectin leucine-rich transmembrane protein 3T cellsHuman T cellsCancer immunotherapyT cell-based cancer immunotherapyInhibit T cell activationT cell checkpointsActivated human T cellsT cell immunityT cell killingT cell activationHuman cancer modelsImmune-dependent mannerAxon guidance proteinsTarget such mechanismsCAR-TCoinhibitory receptorsGuidance proteinsTumor immunityClinical benefitCancer modelsTumor growthCancer cellsHuman cancersMonoclonal antibodiesLeukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice
Singh A, Mommers-Elshof E, Vijver S, Jansen J, Gonder S, Lebbink R, Bihan D, Farndale R, Boon L, Langermann S, Leusen J, Flies D, Meyaard L, Pascoal Ramos M. Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice. Cancer Immunology, Immunotherapy 2024, 73: 16. PMID: 38236251, PMCID: PMC10796629, DOI: 10.1007/s00262-023-03600-6.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsLeukocyte-associated immunoglobulin-like receptor-1Increase tumor controlTumor controlAnti-programmed death-ligand 1Mouse modelT cells in vitroMouse T cells in vitroIncreased tumor clearanceAnti-tumor responsesDeath-ligand 1Immunocompetent mouse modelReduced tumor burdenControl tumor growthHumanized mouse modelIn vivo tumor modelsWild type miceAssociated with tumor developmentPD-L1Tumor burdenTumor clearanceConventional immunotherapyImmunocompetent miceTumor outgrowthTherapy responseTumor microenvironment
2023
LAIR-1 agonism as a therapy for acute myeloid leukemia
Lovewell R, Hong J, Kundu S, Fielder C, Hu Q, Kim K, Ramsey H, Gorska A, Fuller L, Tian L, Kothari P, Paucarmayta A, Mason E, Meza I, Manzanarez Y, Bosiacki J, Maloveste K, Mitchell N, Barbu E, Morawski A, Maloveste S, Cusumano Z, Patel S, Savona M, Langermann S, Myint H, Flies D, Kim T. LAIR-1 agonism as a therapy for acute myeloid leukemia. Journal Of Clinical Investigation 2023, 133: e169519. PMID: 37966113, PMCID: PMC10650974, DOI: 10.1172/jci169519.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaLeukemic stem cellsMyeloid leukemiaPatient-derived xenograft modelsHealthy hematopoietic stem cellsStem cellsCare therapyLAIR-1LSC survivalAML blastsAgonist antibodyTherapeutic strategiesXenograft modelLeukemic cellsTherapeutic potentialHematopoietic stem cellsEffective eradicationTherapyLeukemiaCell deathAgonismSignaling programsCellsPresence of collagenAntibodiesThe Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas
Francis D, Dougan J, Pillsbury C, Park S, Langermann S, Koff J, Li Z, Flowers C, Porter C. The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas. Blood 2023, 142: 4367. DOI: 10.1182/blood-2023-190405.Peer-Reviewed Original ResearchCitationsConceptsDiffuse large B-cell lymphomaB-cell lymphomaAggressive B-cell lymphomasGerminal center B cellsImmune responseBurkitt's lymphomaLymphoma casesDisease progressionSiglec-15Immune deficient (SCID) BALB/c miceR diffuse large B-cell lymphomaB cellsDeficient BALB/c miceLocal anti-tumour immune responseAggressive mature B-cell lymphomaAnti-tumor immune responseBALB/c miceLarge B-cell lymphomaHealthy donor PBMCsIntensive salvage regimensMost diffuse large B-cell lymphomasEvent-free survivalFirst-line treatmentRefractory hematologic malignanciesNon-Hodgkin lymphoma casesMA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC
Gettinger S, Goldberg S, Chiang A, Wilson F, Kim S, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Jackson R, Pope J, Myint H, Langermann S, Cheng W, Rimm D, Chen L, Herbst R. MA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC. Journal Of Thoracic Oncology 2023, 18: s155. DOI: 10.1016/j.jtho.2023.09.224.Peer-Reviewed Original ResearchConceptsAnti‐Siglec‐15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury‐Induced Immobilization in Rats
Peng Y, Langermann S, Kothari P, Liu L, Zhao W, Hu Y, Chen Z, de Lima Perini M, Li J, Cao J, Guo X, Chen L, Bauman W, Qin W. Anti‐Siglec‐15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury‐Induced Immobilization in Rats. JBMR Plus 2023, 7: e10825. PMID: 38130761, PMCID: PMC10731123, DOI: 10.1002/jbm4.10825.Peer-Reviewed Original ResearchAltmetricConceptsAcute spinal cord injurySpinal cord injuryTrabecular bone volumeBone lossBone resorptionBone volumeBone formationRat model of acute spinal cord injuryCultures of bone marrow cellsAntiresorptive agent denosumabInhibition of bone formationSiglec-15Sublesional bone lossBone mineral densityModel of acute spinal cord injuryPrevent bone lossBone marrow cellsInhibit bone lossInhibiting osteoclast maturationMale Wistar ratsEx vivo cultureInhibit bone resorptionSpinal cord transectionAcute SCI modelAntiresorptive agents